Table of Contents

Preclinical Development

• Preclinical Development

  Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes

  Sutapa Banerjee, Scott M. Gianino, Feng Gao, Uwe Christians and David H. Gutmann

  Mol Cancer Ther February 1 2011 10 (2) 279-291; DOI:10.1158/1535-7163.MCT-10-0654

  
  
• Preclinical Development

  Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells

  Seema Gupta, Tulay Koru-Sengul, Susanne M. Arnold, Gayathri R. Devi, Mohammed Mohiuddin and Mansoor M. Ahmed

  Mol Cancer Ther February 1 2011 10 (2) 292-302; DOI:10.1158/1535-7163.MCT-10-0630

  
  
• Preclinical Development

  Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells

  Rouba Hage-Sleiman, Stéphanie Herveau, Eva-Laure Matera, Jean-Fabien Laurier and Charles Dumontet

  Mol Cancer Ther February 1 2011 10 (2) 303-312; DOI:10.1158/1535-7163.MCT-10-0568

  
  
• Preclinical Development

  Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma

  Joslyn Mills, Todd Hricik, Sara Siddiqi and Igor Matushansky

  Mol Cancer Ther February 1 2011 10 (2) 313-324; DOI:10.1158/1535-7163.MCT-10-0724

  
  
• Preclinical Development

  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2

  Siân Rizzo, Jenny M. Hersey, Paul Mellor, Wei Dai, Alessandra Santos-Silva, Daniel Liber, Louisa Luk, Ian Titley, Craig P Carden, Garry Box, David L. Hudson, Stanley B. Kaye and Robert Brown

  Mol Cancer Ther February 1 2011 10 (2) 325-335; DOI:10.1158/1535-7163.MCT-10-0788

  
  
• Preclinical Development

  Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

  Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori and John D. Minna

  Mol Cancer Ther February 1 2011 10 (2) 336-346; DOI:10.1158/1535-7163.MCT-10-0750

  
  
• Preclinical Development

  Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

  Christian Thomas, Amina Zoubeidi, Hidetoshi Kuruma, Ladan Fazli, Francois Lamoureux, Eliana Beraldi, Brett P. Monia, A. Robert MacLeod, Joachim W. Thüroff and Martin E. Gleave

  Mol Cancer Ther February 1 2011 10 (2) 347-359; DOI:10.1158/1535-7163.MCT-10-0850

  
  
• Preclinical Development

  Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

  Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan Henley, Lisa Pickard, Gowri Vijayaraghavan, John J. Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins and Michelle D. Garrett

  Mol Cancer Ther February 1 2011 10 (2) 360-371; DOI:10.1158/1535-7163.MCT-10-0760